The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
|Data di pubblicazione:||2012|
|Titolo:||The impact of proteomics in the understanding of the molecular basis of paclitaxel-resistance in ovarian tumors|
|Autore/i:||Vergara D;Tinelli A;Iannone A;Maffia M|
|Digital Object Identifier (DOI):||10.2174/156800912803251171|
|Codice identificativo ISI:||WOS:000313047700006|
|Codice identificativo Scopus:||2-s2.0-84867793823|
|Citazione:||The impact of proteomics in the understanding of the molecular basis of paclitaxel-resistance in ovarian tumors / Vergara D;Tinelli A;Iannone A;Maffia M. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 12(8)(2012), pp. 987-997.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris